VAERS Reports Y227N

VAERS 2651791

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

schwer

Staat: GA
Alter: 65,0
Geschlecht: M
Eingang: 02.07.2023
Impfdatum: 11.06.2023
Beginn: 19.06.2023
Tage bis Beginn: 8,0
Dosis: 1
Route/Site: IM / LA

Tod: unbekannt Lebensbedrohlich: ja Hospital: ja Disable: unbekannt ER: unbekannt Erholt: nein

Anti-aquaporin-4 antibody negative Blindness CSF glucose increased CSF lymphocyte count normal CSF monocyte count increased CSF oligoclonal band absent CSF protein CSF red blood cell count CSF white blood cell count negative Central nervous system lesion Endotracheal intubation Gait disturbance HIV test negative Immunoglobulin therapy Intensive care Laboratory test Lethargy Lumbar puncture abnormal

Symptomtext

Patient received vaccines on June 11, 2023. Patient developed bilateral blurry vision followed by gait instability on June 19, 2023. Patient was admitted to the hospital on June 20 with complete bilateral blindness. and gait instability. Patient transferred to ICU with lethargy on June 21 and got intubated for airway protection. Patient underwent MRI of orbit concerning for possible demyelinating or autoimmune process on 6/21/23. MRi brain on same day concerning for acute disseminated encephalomyelitis. Patient started on 1000mg Solumedrol on 6/22 and completed 5 days of pulse steroids. Started on IVIG for 5 days on 6/26 due to lack of response. Patient remains unresponsive in our ICU on mechanical ventilation.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Intensive care
Hospital-Tage: 12,0
Labordaten: MRI: Extensive abnormality in the brain with multiple enhancing lesions in the bilateral deep white matter with the posterior predilection, as well as in the midbrain, right superior cerebellar peduncle and left middle cerebellar peduncle, also the left lateral medulla. Appearance is most consistent with a demyelinating process such as ADEM or NMOSD including AQP4 antibody related. Also in the differential is autoimmune disorders such as MOG antibody disease. These findings are not felt to be infectious in etiology. Lumbar puncture 4 WBC (50% lymphcytes, 50% monocytes), 0 RBC, Protein 59, Glucose 116, absent oligoclonal bands. HIV and syphilis screen are negative. AQP4-IGG negative. Anti-MOG is pending.
Aktuelle Erkrankungen: No illness
Vorgeschichte: Paroxysmal atrial fibrillation s/p pacemaker, CAD s/p stent x 1, hyperlipidemia, hypertension, hypothyroidism, BPH
Andere Medikamente: Amlodipine 2.5mg qd Eliquis 5mg BID Aspirin 81mg qd Lipitor 80mg qd colchicine 0.6mg qd Zetia 10mg qd FLonase Synthroid 175mcg qd Losartan 50mg qd Torolol xl 25mg qd Protinix 40mg qd Requip 0.5mg TID
Allergien: no known allergies
Vorherige Impfungen: -

VAERS 2666538

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

moderat

Staat: FL
Alter: 69,0
Geschlecht: F
Eingang: 11.08.2023
Impfdatum: 03.07.2023
Beginn: 04.07.2023
Tage bis Beginn: 1,0
Dosis: 1
Route/Site: IM / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: nein

Arthralgia Back pain C-reactive protein Chest pain Headache Fatigue Joint stiffness Musculoskeletal stiffness Neck pain Laboratory test Pain in extremity Rheumatoid factor Pain

Symptomtext

Previously well 69 year old female received Shingrix vaccine in left arm. Starting 1 day after receiving vaccination, patient developed progressively worsening pain in her left upper extremity that progressed to widespread pain throughout her body, associated with fatigue and headache. Reports significant, persistent pain and stiffness in neck, shoulders, hips, and legs. Patient was seen at urgent care, in PCP office, and by Rheumatology. Treated with multiple courses of NSAIDs and corticosteroids. Diagnosed with possible polymyalgia rheumatica by Rheumatology, still on prednisone therapy.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Chest pain
Hospital-Tage: -
Labordaten: ESR 31, CRP 16 (7/26/23)
Aktuelle Erkrankungen: none
Vorgeschichte: Depression and anxiety
Andere Medikamente: Fluvoxamine Amitriptyline Alprazolam
Allergien: Sulfa
Vorherige Impfungen: -

VAERS 2666538

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

moderat

Staat: FL
Alter: 69,0
Geschlecht: F
Eingang: 11.08.2023
Impfdatum: 03.07.2023
Beginn: 04.07.2023
Tage bis Beginn: 1,0
Dosis: 1
Route/Site: SYR / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: nein

Arthralgia Back pain C-reactive protein Chest pain Headache Fatigue Joint stiffness Musculoskeletal stiffness Neck pain Laboratory test Pain in extremity Rheumatoid factor Pain

Symptomtext

Previously well 69 year old female received Shingrix vaccine in left arm. Starting 1 day after receiving vaccination, patient developed progressively worsening pain in her left upper extremity that progressed to widespread pain throughout her body, associated with fatigue and headache. Reports significant, persistent pain and stiffness in neck, shoulders, hips, and legs. Patient was seen at urgent care, in PCP office, and by Rheumatology. Treated with multiple courses of NSAIDs and corticosteroids. Diagnosed with possible polymyalgia rheumatica by Rheumatology, still on prednisone therapy.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Chest pain
Hospital-Tage: -
Labordaten: ESR 31, CRP 16 (7/26/23)
Aktuelle Erkrankungen: none
Vorgeschichte: Depression and anxiety
Andere Medikamente: Fluvoxamine Amitriptyline Alprazolam
Allergien: Sulfa
Vorherige Impfungen: -

VAERS 2653701

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge y227n

moderat

Staat: FL
Alter: 60,0
Geschlecht: M
Eingang: 07.07.2023
Impfdatum: 07.07.2023
Beginn: 07.07.2023
Tage bis Beginn: 0,0
Dosis: 1
Route/Site: IM / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: nein

Dyspnoea Heart rate increased Malaise Rash Rash erythematous

Symptomtext

patient called an hour after shot saying he is having rash and not feeling well. when he came to pharmacy, he was almost collapsing his wife brought him in, he was having difficulty breathing , high heart rate, and rash red, high patches all over his body ..admistered EPI-PEN and called EMS, he left the store with them symptoms improved 15-20 minutes after the epi-pen injection.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Dyspnoea
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: liver transplant
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: -

VAERS 2648180

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge y227n

moderat

Staat: SC
Alter: 53,0
Geschlecht: F
Eingang: 21.06.2023
Impfdatum: 16.06.2023
Beginn: 17.06.2023
Tage bis Beginn: 1,0
Dosis: 1
Route/Site: IM / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: ja

Arthralgia Neck pain Pain Paraesthesia

Symptomtext

Patient called on the phone stating that after 24 hours of adminstration of shingrix and prevnar 20 vaccine, patient felt tingling sensation and pain that was radiating from neck to hips and outward on the right side. She spoke with intern and pharmacist and was advised to call her doctor right away or go to urgent care.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Paraesthesia
Hospital-Tage: -
Labordaten: Patient went to urgent care and they prescribed benadryl, advised her to take her gabapentin and hydrate.
Aktuelle Erkrankungen: none
Vorgeschichte: cervical radiculopathy
Andere Medikamente: Tramadol 50mg, Gabapentin 300mg, Biktarvy 50/200/25mg, estradiol 0.5mg
Allergien: quinolones
Vorherige Impfungen: -

VAERS 2682066

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

mild

Staat: NC
Alter: 75,0
Geschlecht: M
Eingang: 14.09.2023
Impfdatum: 14.09.2023
Beginn: 14.09.2023
Tage bis Beginn: 0,0
Dosis: 2
Route/Site: IM / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: nein

Dizziness Hypoaesthesia

Symptomtext

Upon receiving the vaccine, the patient was lightheaded and when sitting in the chair started to feel numb & "like insides were shaking". Patient reported only having eaten cereal & jello all day and had taken hydralazine & carvedilol about an hour before coming for immunization. EMS was contacted and upon evaluation patient was transported to local hospital.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Dizziness
Hospital-Tage: -
Labordaten: none reported
Aktuelle Erkrankungen: none reported
Vorgeschichte: high blood pressure
Andere Medikamente: Amlodipine, Hydralazine, Carvedilol
Allergien: none reported
Vorherige Impfungen: -

VAERS 2670935

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge y227n

mild

Staat: KS
Alter: 70,0
Geschlecht: F
Eingang: 14.08.2023
Impfdatum: 10.08.2023
Beginn: 14.08.2023
Tage bis Beginn: 4,0
Dosis: 1
Route/Site: IM / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Injection site pain Pain Pain in extremity Product administered at inappropriate site

Symptomtext

pt c/o of arm pain radiating down from injection site to rest of lower right arm. Pt states vaccine administration site was "too low". No issue of arm pain with other shoulder. Pt states using lidocaine patch below injection site , and also taking generic Norco to relieve arm/shoulder pain. Pt vaccine on 8/10/23, pain reported on 8/14/23.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Injection site pain
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: n/a
Vorgeschichte: nkhc
Andere Medikamente: phentermine 15mg caps
Allergien: nkda
Vorherige Impfungen: -

VAERS 2664288

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

mild

Staat: NC
Alter: 75,0
Geschlecht: F
Eingang: 01.08.2023
Impfdatum: 01.07.2023
Beginn: 01.07.2023
Tage bis Beginn: 0,0
Dosis: 1
Route/Site: IM / RA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Injection site rash Rash erythematous

Symptomtext

Patient had red rash at site in injection that spread on arm to bicep area

Weitere VAERSDATA-Felder

Praegender Schweregrund: Injection site rash
Hospital-Tage: -
Labordaten: N/A
Aktuelle Erkrankungen: None
Vorgeschichte: None
Andere Medikamente: Zetia, Warfarin, Synthroid
Allergien: Sulfa Drugs
Vorherige Impfungen: -

VAERS 2659339

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge y227n

mild

Staat: NC
Alter: 52,0
Geschlecht: F
Eingang: 21.07.2023
Impfdatum: 10.07.2023
Beginn: 10.07.2023
Tage bis Beginn: 0,0
Dosis: 1
Route/Site: IM / RA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Burning sensation Immediate post-injection reaction Impaired work ability Injection site bruising Injection site pain Neuropathy peripheral Pain in extremity Peripheral swelling

Symptomtext

Immediate pain at injection that went down arm. RPH dismissed as burning from shingrix. Patient came back to pharmacy on 7/21 after seeing PCP about the pain in arm. Right arm is visibly bruised at injection site which seems to be given in acromium process. Patient's arm was swollen with neuropathy going to arm. Patient is a massage therapist and this affected her line of work

Weitere VAERSDATA-Felder

Praegender Schweregrund: Injection site bruising
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: -
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: -

VAERS 2658876

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

mild

Staat: TX
Alter: 83,0
Geschlecht: F
Eingang: 20.07.2023
Impfdatum: 10.07.2023
Beginn: 11.07.2023
Tage bis Beginn: 1,0
Dosis: 2
Route/Site: IM / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja

Headache Myalgia Peripheral swelling Rash

Symptomtext

The patient came in 7-18-23 in the evening and said that she experienced some arm swelling, muscle pains, headache, and a slight rash on a small area on her upper back from her vaccination on 7-10-23. The symptoms resolved but she did let her doctor know at a doctor visit.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Headache
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: -
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: -

VAERS 2649188

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

mild

Staat: OR
Alter: 54,0
Geschlecht: M
Eingang: 25.06.2023
Impfdatum: 22.06.2023
Beginn: 23.06.2023
Tage bis Beginn: 1,0
Dosis: 2
Route/Site: IM / RA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja

Body temperature increased Disorientation Fatigue Injection site pain Pain

Symptomtext

Significant fatigue, mild body aches, slight disorientation, slightly elevated temperature (did not measure) for 18 hours after initial onset of symptoms. Tenderness at injection site 72 hrs after injection.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Fatigue
Hospital-Tage: -
Labordaten: None
Aktuelle Erkrankungen: None
Vorgeschichte: Mixed hyperlipidemia
Andere Medikamente: Daily Multi, Iron 65 mg, Fish Oil 1400 mg, Calcium 600 mg, D3 50 mcg
Allergien: None known
Vorherige Impfungen: -

VAERS 2640495

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

mild

Staat: MO
Alter: 81,0
Geschlecht: F
Eingang: 13.06.2023
Impfdatum: 03.06.2023
Beginn: 01.06.2023
Tage bis Beginn: -
Dosis: 1
Route/Site: IM / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Acne Chills Erythema Pain Pruritus Injection site pain Injection site rash Injection site swelling Rash pustular Pustule Pyrexia

Symptomtext

Redness; Itching; Stinging; Pustules with whiteheads; Fever; Chills; Pustules; This non-serious case was reported by a consumer via call center representative and described the occurrence of erythema in a 81-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 03-JUN-2023, the patient received the 1st dose of Shingrix (left arm). In JUN-2023, an unknown time after receiving Shingrix, the patient experienced erythema (Verbatim: Redness), pruritus (Verbatim: Itching), stinging (Verbatim: Stinging), whiteheads (Verbatim: Pustules with whiteheads), fever (Verbatim: Fever), chills (Verbatim: Chills) and pustular rash (Verbatim: Pustules). The outcome of the erythema, pruritus, stinging, whiteheads and pustular rash were not resolved and the outcome of the fever and chills were resolved. It was unknown if the reporter considered the erythema, pruritus, stinging, whiteheads, fever, chills and pustular rash to be related to Shingrix. It was unknown if the company considered the erythema, pruritus, stinging, whiteheads, fever, chills and pustular rash to be related to Shingrix. Additional Information: GSK Receipt Date: 05-JUN-2023 The reporter was a patient. The patient received her first dose of Shingrix and had redness, itching, stinging and pustules with whiteheads on her left arm. The reporter stated that all the symptoms were still ongoing. The reporter also mentioned that she had fever and chills which resolved. The reporter did consent to follow up. This case had been link to US2023079169 reported by same reporter.; Sender's Comments: US-GSK-US2023079169:same reporter

Weitere VAERSDATA-Felder

Praegender Schweregrund: Injection site pain
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: -
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: -

VAERS 2643791

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge y227N

mild

Staat: GA
Alter: 81,0
Geschlecht: F
Eingang: 10.06.2023
Impfdatum: 06.06.2023
Beginn: 06.06.2023
Tage bis Beginn: 0,0
Dosis: 1
Route/Site: IM / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Injection site erythema Injection site pruritus Injection site swelling Swelling

Symptomtext

Pt reports swelling, redness, itchiness at sight of injection. There was noticeable swelling

Weitere VAERSDATA-Felder

Praegender Schweregrund: Injection site erythema
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: -
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: Pt reports similar response to steroid shot within previous year

VAERS 2641050

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

mild

Staat: NJ
Alter: 71,0
Geschlecht: F
Eingang: 05.06.2023
Impfdatum: 31.05.2023
Beginn: 31.05.2023
Tage bis Beginn: 0,0
Dosis: 1
Route/Site: IM / LA

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Balance disorder Dizziness

Symptomtext

dizziness, started a few hours after the injection. lasted 5 days (6/5/2023). able to walk, but feels wabbly. no n/v.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Dizziness
Hospital-Tage: -
Labordaten: none
Aktuelle Erkrankungen: HTN
Vorgeschichte: HTN
Andere Medikamente: none
Allergien: Shell fish, butalbital, peanuts, pork
Vorherige Impfungen: -

VAERS 2718724

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

gering

Staat: CA
Alter: 80,0
Geschlecht: M
Eingang: 29.11.2023
Impfdatum: 08.04.2022
Beginn: 08.04.2022
Tage bis Beginn: 0,0
Dosis: 4
Route/Site: - / -

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Extra dose administered

Symptomtext

received the 1st dose of Shingrix on 13Nov2020, 2nd dose on 14Jan2021, an accidental 3rd dose on 08Apr2022 and an accidental 4th Dose on 08Sep2023; received the 1st dose of Shingrix on 13Nov2020, 2nd dose on 14Jan2021, an accidental 3rd dose on 08Apr2022 and an accidental 4th Dose on 08Sep2023; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 80-year-old male patient who received Herpes zoster (Shingrix) (batch number Y227N, expiry date 25-OCT-2025) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 13th November 2020) and Shingrix (received 2nd dose on 14th January 2021). On 08-SEP-2023, the patient received the 4th dose of Shingrix. On 08-APR-2022, the patient received the 3rd dose of Shingrix. On 08-APR-2022, not applicable after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: received the 1st dose of Shingrix on 13Nov2020, 2nd dose on 14Jan2021, an accidental 3rd dose on 08Apr2022 and an accidental 4th Dose on 08Sep2023). On 08-SEP-2023, the patient experienced extra dose administered (Verbatim: received the 1st dose of Shingrix on 13Nov2020, 2nd dose on 14Jan2021, an accidental 3rd dose on 08Apr2022 and an accidental 4th Dose on 08Sep2023). The outcome of the extra dose administered and extra dose administered were unknown. Additional Information: GSK receipt date: 16-NOV-2023 The pharmacist reported that a patient received the 1st dose, 2nd dose, an accidental 3rd dose and an accidental 4th Dose. The health care professional (HCP) stated that the patient reported that he was feeling fine. Accidentally the patient received 2 extra Shingrix dose, which led to extra dose administered The reporter consented to follow up via email.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Extra dose administered
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: -
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: -

VAERS 2673407

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

gering

Staat: -
Alter: 61,0
Geschlecht: F
Eingang: 18.08.2023
Impfdatum: 09.08.2023
Beginn: 09.08.2023
Tage bis Beginn: 0,0
Dosis: 3
Route/Site: - / -

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Overdose

Symptomtext

supposed to receive the 2nd dose of Shingrix received two doses of the same vaccine on the same visit; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of overdose in a 61-year-old female patient who received Herpes zoster (Shingrix) (batch number Y227N, expiry date 25-OCT-2024) for prophylaxis. Concomitant products included VARICELLA ZOSTER VACCINE RGE (CHO) (SHINGRIX). On 09-AUG-2023, the patient received the 3rd dose of Shingrix. On 09-AUG-2023, an unknown time after receiving Shingrix and SHINGRIX, the patient experienced overdose (Verbatim: supposed to receive the 2nd dose of Shingrix received two doses of the same vaccine on the same visit). The outcome of the overdose was unknown. Additional Information: GSK Receipt Date:09-AUG-2023 The reporter informed that earlier that day, a patient that was supposed to receive the 2nd dose of Shingrix received two doses of the same vaccine on the same visit, which led to overdose. The reporter consented to follow up.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Overdose
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: -
Andere Medikamente: SHINGRIX
Allergien: -
Vorherige Impfungen: -

VAERS 2652876

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

gering

Staat: -
Alter: -
Geschlecht: F
Eingang: 05.07.2023
Impfdatum: 30.06.2023
Beginn: 30.06.2023
Tage bis Beginn: 0,0
Dosis: 2
Route/Site: - / -

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Inappropriate schedule of product administration

Symptomtext

Shingrix early second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 75-year-old female patient who received Herpes zoster (Shingrix) (batch number Y227N, expiry date 25-OCT-2024) for prophylaxis. Concomitant products included VARICELLA ZOSTER VACCINE RGE (CHO) (SHINGRIX). On 30-JUN-2023, the patient received the 2nd dose of Shingrix. On 30-JUN-2023, an unknown time after receiving Shingrix and an unknown time after receiving SHINGRIX, the patient experienced drug dose administration interval too short (Verbatim: Shingrix early second dose). The outcome of the drug dose administration interval too short was unknown. Additional Information: GSK receipt date 30 Jun 2023: The pharmacist reported an early second dose of Shingrix was administered. The patient consented to follow up via email. The patient received early second dose of Shingrix which led to shortening of vaccination schedule.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Inappropriate schedule of product administration
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: -
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: -

VAERS 2639867

GLAXOSMITHKLINE BIOLOGICALS · ZOSTER (SHINGRIX) · Charge Y227N

gering

Staat: TN
Alter: 62,0
Geschlecht: M
Eingang: 01.06.2023
Impfdatum: 27.05.2023
Beginn: 27.05.2023
Tage bis Beginn: 0,0
Dosis: 3
Route/Site: - / -

Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein

Extra dose administered

Symptomtext

Shingrix 3 doses administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 62-year-old male patient who received Herpes zoster (Shingrix) (batch number Y227N, expiry date 25-DEC-2023) for prophylaxis. Previously administered products included shingrix (received 1st dose on 20th December 2022). Concomitant products included VARICELLA ZOSTER VACCINE RGE (CHO) (SHINGRIX). On 27-MAY-2023, the patient received the 3rd dose of Shingrix. On 27-MAY-2023, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Shingrix 3 doses administered). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 30-MAY-2023 The reporter reported that the patient received 3 doses of Shingrix which led to extra dose administered. The reporter asked was there any safety data. The Vaccine Administration Facility was the same as Primary Reporter. The reporter consented to follow up.

Weitere VAERSDATA-Felder

Praegender Schweregrund: Extra dose administered
Hospital-Tage: -
Labordaten: -
Aktuelle Erkrankungen: -
Vorgeschichte: -
Andere Medikamente: -
Allergien: -
Vorherige Impfungen: -